id	等位基因	注释文本
1232	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the 6 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.
1231	*5	The CYP2D^5 allele is assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.
1230	*4xN	The CYP2D64xN allele (4x2) is assigned as a no function allele by CPIC. Patients carrying the *4xN allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.
1229	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.
1228	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients carrying the 3 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.
1227	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with atomoxetine may have a decreased, but not absent, risk for treatment related side effects as compared to patients with two no function alleles. Other genetic and clinical factors may also influence response to atomoxetine.

id	证据的ID	总结
2734	1446896699	CYP2D6 3/3 + 3/4 + 3/5 + 3/6 + 4/4 + 4/4xN + 4/5 + 4/6 + 5/5 + 4xN/5 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 1/3 + 1/4 + 1/5 + 1/6 + 1/7 + 1/1xN + 1/1 + 1/10 + 1/17 + 3/10 + 4/10 + 4/17 + 5/10 + 5/17 + 6/10 + 10/10 + 10/17 + 17/17.
2733	1183688875	CYP2D6 poor metabolizers are not associated with clinically significant change in QT(c) when exposed to atomoxetine in healthy individuals.
2732	PA166104989	Annotation of DPWG Guideline for atomoxetine and CYP2D6
2731	PA166181885	Annotation of CPIC Guideline for atomoxetine and CYP2D6

id	类型	评论
1358	Update	Edited phenotype descriptions
1357	Update	Added DPWG guideline as evidence
1356	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1355	Update	Removed conflicting evidence statement because it was from variant annotation that did not specify alleles.
1354	Update	Attached CPIC guideline and removed override. Added conflicting evidence statement.
1353	Create	Created

最新招商产品更多>>